Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

J Clin Oncol 2014 May 1

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

Related Questions

How do you determine the choice of therapy for platinum resistant ovarian cancer in healthy, good performance status patients?

Two new phase 2 studies this year with apatinib/oral etoposide (AEROC) and sorafenib/topotecan (TRIAS) were released, and NCCN also lists many single ...

New comment by at VA Boston Healthcare System ( January 15, 2019)

i agree

Read more (3 Answers available)

What treatment options would you consider for a metastatic low grade serous ovarian carcinoma that transforms to high grade?

Patient has been treated with carbo/taxol, hormonal therapies, and trametinib to date.

New answer by at UCLA David Geffen School of Medicine/UCLA Medical Center (October 19, 2020)

A couple of things to consider for this case, #1 treatment-free interval #2 platinum-free interval #3 bulky disease? #4 recent tumor profiling #5 HRD status? I am assuming tha...

Read more (1 Answer available)

How would you treat IIB ovarian carcinosarcoma which recurred locally at 1 month post initial debulking surgery, progressed through 2 cycles of adjuvant carbo/taxol, and is now s/p repeat debulking?

Tumor is HER2 3+ on IHC staining.

New answer by Medical Oncologist at University of Utah School of Medicine (December 12, 2024)

Also please consider a clinical trial for this patient; especially with HER2 targeted agent.

Read more (2 Answers available)